Abstract 19828: Real-world Assessment of Patients Switching From Warfarin to Non-vitamin K Oral Anticoagulants Using MarketScan EarlyView Data

Background: Non-valvular atrial fibrillation (NVAF) was commonly treated with warfarin. With the introduction of Non-Vitamin K Oral Anticoagulants (NOACs) in the United States, some patients are switching from standard of care to NOACs Purpose: To investigate demographic and clinical characteristics associated with switching among NVAF patients treated with warfarin to a NOAC (apixaban, dabigatran and rivaroxaban). Methods: A retrospective cohort study was conducted using Truven MarketScan EarlyView data. The patient recruitment period was from 01/12/2012 to 01/31/2015. Study enrolled adult NVAF patients ≥18 years with 2 or more warfarin prescriptions at least 90 days apart, with 6 months continuous enrollment prior to their last warfarin prescription. Warfarin switch to NOAC will be defined for patients who had a pharmacy claim of NOACs within 60 days from the last day of supply of the last filled prescription of warfarin. Stepwise logistic regression was used to identify patient characteristics associat...